Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gataparsen + Docetaxel in Hormone Refractory Prostate Cancer
NCT00642018Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Aug 2011
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of gataparsen in prostate cancer (PCa) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Progression-free Survival at 44.68 months and Number of Participants With Adverse Events at 19 months. Started Mar 2008; status: completed.
02
Drugs
gataparsen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00642018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642018.